Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome

Trials

Volumn 14, Issue 1, 2013, Pages

  Choodari Oskooei, Babak ^a   Parmar, Mahesh K B ^a   Royston, Patrick ^a   Bowden, Jack ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BOOTSTRAPPING; CLINICAL TRIAL (TOPIC); FOLLOW UP; HUMAN; RETROSPECTIVE STUDY; SIMULATION; STUDY DESIGN; SYSTEMATIC ERROR; TWO ARM MULTISTAGE TRIAL;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIALS; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SAMPLE SIZE; SELECTION BIAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872592627     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-23     Document Type: Article

References (21)

1. Royston P, Barthel FMS, Parmar MKB, Choodari-Oskooei B, Isham V. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of efficacy. Trials 2011, 12:81. 10.1186/1745-6215-12-81, 3078872, 21418571.
2. Piantadosi S. Clinical Trials: A Methodologic Perspective 2005, New York: John Wiley.
3. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MKB. Stampede: systemic therapy for advancing or metastatic prostate cancer.a multi-arm multi-stage randomised controlled trial. Clin Oncol 2008, 20:577-581.
4. Emerson SS. Issues in the use of adaptive clinical trial designs. Stat Med 2006, 25:3270-3296. 10.1002/sim.2626, 16906553.
5. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes, with an application in ovarian cancer. Stat Med 2003, 22(14):2239-2256. 10.1002/sim.1430, 12854091.
6. Barthel FMS, Royston P, Parmar MKB. A menu-driven facility for sample size calculation in novel multi-arm, multi-stage randomised controlled trials with a time-to-event outcome. Stata J 2009, 9(4):505-523.
7. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model 2000, New York: Springer.
8. Zhang JJ, Blumenthal GM, He K, Tang S, Cortazar P, Sridhara R. Overestimation of the effect size in group sequential trials. Clin Cancer Res 2012,
9. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol 2009, 27:1419-1425. 10.1200/JCO.2008.19.1684, 2668552, 19224846.
10. MRC Renal Cancer Collaborators Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised trial. Lancet 1999, 353:14-17. MRC Renal Cancer Collaborators.
11. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RTD, Mardiak J, Hussain T, Sylvester R, Parmar MKB, Royston P, Mulders PFA. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010, 375:641-648. 10.1016/S0140-6736(09)61921-8, 2835851, 20153039.
12. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002, 360:505-515. The International Collaborative Ovarian Neoplasm (ICON) Group.
13. The ICON and AGO Collaborators Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-2.2 trial. Lancet 2003, 361:2099-2106. The ICON and AGO Collaborators.
14. Barthel FMS, Parmar MKB, Royston P. How do multi-stage multi-arm trials compare to the traditional two-arm parallel group design - a reanalysis of 4 trials. Trials 2009,
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
16. Goodman SN. Stopping trials for efficacy: an almost unbiased view. Clin Trials 2009, 6:133-135. 10.1177/1740774509103609, 19342465.
17. Freidlin B, Korn EL. Stopping clinical trials early for benefit: impact on estimation. Clin Trials 2009, 6:119-125. 10.1177/1740774509102310, 19342463.
18. Cohen A, Sackrowitz H. Two stage conditionally unbiased estimators of the selected mean. Stat Probability Lett 1989, 8:273-278.
19. Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical J 2008, 50(4):515-527.
20. Sill MW, Sampson AR. Extension of a two-stage conditionally unbiased estimator of the selected population to the bivariate normal case. Commun Stat Theory Methods 2007, 36:801-813.
21. Bauer P, Koenig F, Brannath W, Poscha M. Selection and bias - two hostile brothers. Stat Med 2010, 29(1):1-13.